All News

obese.waist_.jpg

Weekly Semaglutide for Weight Loss in Adults

Jack Cush, MD

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.

Read Article
COVID vaccine vials

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Jack Cush, MD

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.

Read Article
gene signature RNA

Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA

Jack Cush, MD

RNA sequencing and classification of RA subsets has proven useful. RNA sequencing-based stratification of RA synovial tissue showed stronger associations with clinical responses compared with histopathological classification. Additionally, for patients with low or absent B-cell lineage expression signature in synovial tissue, tocilizumab is more effective than rituximab.

Read Article
cardiac2.jpg (keep)

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Jack Cush, MD

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

Read Article
FDA-Building_1.png

Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA

Jack Cush, MD

The FDA has notified healthcare professionals of a safety alert concerning tofacitinib (Xeljanz), noting that preliminary results from a long-term safety clinical trial show an increased risk of serious heart-related problems and cancer with tofacitinib (compared to adalimumab) when given to

Read Article
Dr. Troum considers curcumin 500mg with black pepper BID for patients with inflammatory arthritis. Unclear if there is a relationship or need for monitoring for those with concomitant NSAIDs. #RWCS2021 #RWCS @RWCSmtg @RheumNow https://t.co/9sSWwWTtyv
Dr. Rachel Tate uptoTate ( View Tweet)
1975: Nixon & Bresnev, in effort of medical diplomacy, cooperated on JRA trials. (Fact: Stalin's personal physician was a rheumatologist.) Dr. Steven's shares an interesting historical slide about this collaboration. #RWCS2021 #RWCS @RWCSmtg @RheumNow https://t.co/Px71qfqDcy
Dr. Rachel Tate uptoTate ( View Tweet)
309 RA pts from the Preconception Counseling in Active RA (PreCARA) cohort were treated according to a modified T2T approach, 188 children were born. 47% of pts were on a TNFi during Preg; 75% were in LDAremission before PREG but 90% by 3rd trimester https://t.co/eLffxrH0UV

Links:

Dr. John Cush RheumNow ( View Tweet)

Synovial Tissue Signature Guiding Targeted IL-6 Therapy in RA RNA sequencing-based stratification of rheumatoid arthritis synovial tissue showed stronger associations with clinical responses compared with histopathological classification. https://t.co/VZJuoZ3b5a https://t.co/QxDlnrrywE

Links:

Dr. John Cush RheumNow ( View Tweet)
402 RA pts in RA-Paz registry, starting bDMARD betw 2000 - 2019, had 10% refractory to multiple biologics. Difficult or multi-biologic refractory Dz predicted by erosions, younger age, high baseline DAS-28, unable to lower DAS < 1.2 @6 mo (OR 11.1) https://t.co/GYJ69dgCtr

Links:

Dr. John Cush RheumNow ( View Tweet)

Cardiac and Cancer Signals Tofacitinib Safety Alert from FDA The FDA has notified healthcare professionals of a safety alert concerning tofacitinib when given to at-risk RA patients. https://t.co/RJD8CMouHK https://t.co/j8DMyxsaaf

Links:

Dr. John Cush RheumNow ( View Tweet)
Vagal Nerve Stimulation in Rheumatoid Arthritis Lancet Rheumatology has reported the results of a proof of concept trial, wherein vagal nerve stimulation was shown to ameliorate rheumatoid arthritis (RA) disease activity. https://t.co/XKH0ZY2A7E https://t.co/41nIxMb3e6

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d QD Clinics (123-127; Feb 5) QD127 - Chronic Monarthritis QD126 - Fever by the Numbers QD125 - "What Were You Thinking" QD124 - No Win Consults QD123 - When RA Meets UC https://t.co/ReOFOVooje

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast is up! Tofacitinib Safety Concerns - covering vagal nerve stimulation, IL-23 in PsA, Diet & RA, NSAIDs & COVID, Plaquenil side effects and more. Watch it here>> https://t.co/7RDZ0avZLC ListeniTunes>>https://t.co/FHJv01AAbC or SoundCloud>>https://t.co/yJWJNa6CRL

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Chronic Monarthritis Treatment Considerations on Chronic Monarthritis https://t.co/7VmH1skHhb

Links:

Dr. John Cush RheumNow ( View Tweet)

Download available--30 FDA Approved Biologics in Rheumatology https://t.co/HSvllkDUz7

Links:

Dr. John Cush RheumNow ( View Tweet)

OpenSAFELY analysis shows that NSAIDs safe w/ COVID. Study 1: 1/2 million NSAID users vs ~2 mill non-users found no difference in COVID-19 death (HR 0.96); Study 2: 1.7 million RA/OA pts, 10% on NSAIDs had a lower risk of COVID-19 death (HR 0.78) https://t.co/1f3JBmaf2e

Links:

Dr. John Cush RheumNow ( View Tweet)

More on Vagal Nerve Stimulation in RA (https://t.co/OykGWP76qd) The device used was an earbud, designed to deli)ver electrical pulse sequences to target the cholinergic anti-inflammatory pathway. They called this neural input methodology, e-mmunotherapy https://t.co/iubW0sZgIs https://t.co/cKlzRXKkLT

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Canada Approves Subcutaneous Infliximab Biosimilar The infliximab biosimilar CT-P13, developed by Celltrion and marketed as Remsima has been approved by HealthCanad for subcutaneous (SC) use in all the indications for infliximab. https://t.co/7pS7y4sys9

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of 3 cross-sectional & 2case-control studies shows that the risk of developing #RA is elevated in patients with Crohns colitis (RR = 3.14; 95% CI: 2.46–4.01) and ulcerative colitis (RR = 2.29; 95% CI: 1.76–2.97) https://t.co/TIpd6lh5IZ

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×